Rockwell Medical Receives Nasdaq Delisting Notice for Minimum Bid Price Deficiency

summarizeSummary

Rockwell Medical, Inc. has received an official notice from Nasdaq regarding non-compliance with the minimum $1.00 bid price requirement, initiating a 180-day compliance period to regain compliance.

check_boxKey Events

• Nasdaq Delisting Notice Received

  Rockwell Medical, Inc. received a written notice from Nasdaq on May 8, 2026, indicating non-compliance with the minimum bid price requirement of $1.00 per share.

• Minimum Bid Price Deficiency

  The company's common stock has traded below $1.00 for 30 consecutive business days, triggering the non-compliance notification.

• 180-Day Compliance Period

  Nasdaq has granted an initial 180-calendar day period, until November 4, 2026, for the company to regain compliance. During this time, the stock will continue to be listed and traded.

• Proposed Reverse Stock Split

  The company plans to address the deficiency by proposing a reverse stock split at its 2026 Annual Meeting of Stockholders, a measure previously outlined in its DEF 14A filing on April 30, 2026.

auto_awesomeAnalysis

Rockwell Medical has received a formal notice from Nasdaq indicating non-compliance with the minimum $1.00 bid price requirement. This is a critical development as continued listing on Nasdaq is vital for liquidity and investor confidence, especially for a nano-cap company. While the company has a 180-day period to regain compliance and has proposed a reverse stock split (as disclosed in the DEF 14A on April 30, 2026) as a potential solution, the official notice formalizes a significant risk. This negative corporate governance news comes just one day after the company reported Q1 2026 results and issued strong 2026 guidance, creating conflicting signals for investors.